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In-stent restenosis (ISR) is a novel pathobiologic process, histologically distinct from
restenosis after balloon angioplasty and comprised largely of neointima formation. As
percutaneous coronary intervention increasingly involves the use of stents, ISR is also
becoming correspondingly more frequent. In this review, we examine the available studies of
the histology and pathogenesis of ISR, with particular reference to porcine and other animal
models. An overview of mechanical treatments is then provided, which includes PTCA,
directional coronary atherectomy and high speed rotational atherectomy. Radiation-based
therapies are discussed, including a summary of current problems associated with this
modality of treatment. Finally, novel strategies for the prevention of ISR are addressed,
including novel developments in stents and stent coatings, conventional drugs, nucleic
acid-based drugs and gene transfer. Until recently, limited pharmacologic and mechanical
treatment options have been available for both treatment and prevention of ISR. However,
recent advances in gene modification and gene transfer therapies and, more particularly, in
local stent-based drug delivery systems make it conceivable that the incidence of ISR will now
be seriously challenged. (J Am Coll Cardiol 2002;39:183–93) © 2002 by the American
College of Cardiology
Restenosis, defined as “the arterial healing response after
injury incurred during transluminal coronary revasculariza-
tion” (1) has been the principal drawback of coronary
angioplasty since its inception nearly 25 years ago. The only
widely accepted means of reducing restenosis has been the
coronary stent, and the last five years have seen a prompt
and widespread adoption of coronary stents, following the
demonstration of reduced restenosis rates compared with
percutaneous transluminal coronary angioplasty (PTCA)
alone for comparable lesions (2–4). Coronary revasculariza-
tion now generally involves the use of a stent in more than
70% of cases (5). Coincident with this increased stent use
has been the more widespread treatment of more complex
lesions and the realization that in-stent restenosis (ISR)
occurs in 10% to 50% of cases currently treated in everyday
practice and estimated to have occurred in 150,000 patients
in 1999 in the U.S. alone (6–9). Therefore, the problem of
ISR is becoming at least as important as restenosis after
PTCA.
In-stent restenosis has been classified on the basis of
length of restenosis in relation to stented length (10). Four
types of ISR have been defined: I) focal (10 mm length);
II) diffuse (ISR10 mm within the stent); III) proliferative
(ISR 10 mm extending outside the stent); and IV)
occlusive ISR. Type I has been further subdivided into types
IA to ID based on the site of focal ISR in relation to the
stent (10). An additional type of ISR has been proposed,
that of “aggressive ISR,” defined as ISR that is longer
and/or more severe than the original lesion (9). This type is
noteworthy in that the clinical course is not benign, with
patients more likely to have more severe symptoms and
higher rates of myocardial infarction (9).
Histologically, ISR is quite distinct from restenosis after
balloon angioplasty (1,11,12). Postangioplasty restenosis is
thought to involve vessel elastic recoil, negative remodelling
or contraction, thrombus at the site of injury, smooth
muscle cell (SMC) proliferation and migration and exces-
sive extracellular matrix production. These last two pro-
cesses contribute to neointima (NI) formation (1,13). In
contrast, intravascular ultrasound studies suggest that stent-
ing virtually eliminates vessel elastic recoil and negative
remodelling and that ISR is largely a result of NI formation
alone (12,14,15). Neointima is composed principally of
proliferating SMC (16,17) and extracellular matrix (18).
Peristent thrombus has not been thought to play an impor-
tant role in NI formation—at least in the pig model of
stenting (19)—although recent observations suggest it may
have some influence, particularly in the setting of hypergly-
cemia (20–22).
A number of variables are known to increase the risk of
ISR. Patients with diabetes or a history of prior restenosis
have a higher rate of ISR (23,24). There is some evidence
that genetic factors play a role, examples being the PIA
polymorphism of glycoprotein IIIa and a mutant form of
methylenetetrahydrofolate reductase that appear to increase
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the risk of ISR, whereas allele 2 of the interleukin IL-1ra
gene appears to be protective (25–28). Patients positive for
allergic patch-test reactions to the stent components nickel
and molybdenum also appear to have increased rates of ISR
(29). Procedural-related variables have also been implicated.
For example, the greater the stented length, the number of
stents used or lesions in vessels that are small, occluded, at
vessel ostia or in vein grafts are all associated with increased
ISR rates (30–35). The postprocedural minimal lumen
diameter is also an important, well-documented predictor of
subsequent ISR rates (36).
Animal models of ISR. Animal models have provided
insights into the mechanisms of ISR and are widely used to
evaluate candidate drug inhibitors of ISR (1,37). The
principal model currently used is that of porcine coronary
stenting (38), although stenting of the porcine carotid and
iliac arteries has been described (39,40), and similar models
have also been proposed in the rat, rabbit and primate
(41–43). These small animal models of rat carotid and
rabbit iliac stenting have the advantages of availability and
low cost but are in peripheral vessels, histologically quite
distinct from human coronaries, and are not widely used
(37). Large animal models of nonhuman primates have also
been proposed as models of ISR, given that many species
develop spontaneous atherosclerosis with lesions similar to
humans (44,45), but animals are expensive and difficult to
maintain (37), and most studies have been reported using
peripheral vessels (46,47).
The porcine model of ISR is currently and widely used
(37). In this model, oversized metallic stents are placed into
the coronary arteries of domestic crossbred swine. A thick
NI is reliably induced by 28 days (Fig. 1). The model is
attractive for a number of reasons; the response to deep
injury is very similar between domestic pig and normal
human coronary arteries (48), and the adaptive response in
the pig is more profound in pigs fed a hypercholesterolemic
diet (49). Moreover, since the size and anatomic distribu-
tion of porcine coronary arteries are similar to those of the
human, angiography, intravascular ultrasound, instrumen-
tation and stent deployment are all similar to the clinical
situation.
The porcine model is also useful in that the degree of
injury can be quantitated. The anatomic depth to which the
stent strut penetrates the vessel wall has been correlated with
the induced NI thickness (38). For stents with multiple
struts, an “injury score” can be derived for each strut and a
mean score for the vessel as a whole (Fig. 1). Injury score
can then be correlated to the vessel cross-sectional mean NI
area (38) or percent stenosis (50). More recently, in addition
to the injury score an “inflammation score” has also been
described (50). This is derived from the extent and severity
of inflammatory cell infiltrate around the stent struts. A
correlation exists between the inflammatory score and the
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Figure 1. In-stent restenosis after porcine coronary stenting. Nonathero-
sclerotic porcine coronary artery 30 days after stenting with oversized
balloon. Vessel excised, processed in methylmethacrylate, cut, polished and
stained with haemotoxylin and eosin (originally at 2 magnification). The
injury score for each stent strut is shown according to the definitions: 0 
internal elastic lamina (IEL) intact, endothelium denuded, media com-
pressed but not lacerated; 1  IEL lacerated, media compressed but not
lacerated; 2  IEL lacerated, media lacerated, external elastic lamina
(EEL) compressed but not lacerated; 3  EEL lacerated, media contains
large lacerations, stent strut may extend into the adventitia. The injury
score for the vessel section is calculated as (total of individual stent strut
injury scores) / (number of stent struts in section) and equals 21/10  2.1
based on the original description (38). L  lumen; M  media; N 
neointima; S  stent strut; Th  thrombus.
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degree of arterial injury and with NI thickness, suggesting
inflammation also plays an important role in this model
(50).
There is a time-dependent progression in the cellular
response to stenting in the pig model (19). At 24 h after
stenting, immediately adjacent to the stent struts, there are
acute inflammatory cells and thrombus, containing platelets
and fibrin (19). At one week, this thrombus has become
organized, and macrophages are evident. By two to four
weeks, although some chronic inflammatory cells remain,
the predominant cell type is the fully differentiated SMC
(19). Although histologic studies in the human are neces-
sarily less detailed, a similar progression of thrombus for-
mation, inflammatory cell and SMC infiltration has been
observed from postmortem studies (22).
Despite these similarities, the pig model, like other
models, has limitations. The preinjured arteries are normal,
nonatherosclerotic vessels (38). In the pig, the stent struts
induce injury directly, by medial cell compression or lacer-
ation (38). In the human, direct medial injury occurs by only
32% of stent struts, with most struts being in contact with
atheromatous plaque and not media (22). Thus, in the
human, a stent strut “injury score” is not a practical
calculation, but it is noteworthy that the amount of NI
formation increases with increasing stent area relative to
proximal reference lumen area (22). Another difference
between the models is that in the pig the degree of ISR is
examined at one month, compared with the three to six
months that is the peak period of ISR development in
humans (3,51). Despite these limitations, the porcine cor-
onary model has gained the most widespread use of any of
the large animal models (37) and continues to be used to
evaluate potential new antirestenotic drugs (52), gene-based
(53) and radiation-based therapies (54).
TREATMENTS FOR ISR
In any discussion of the modalities of treatment for ISR it
should be pointed out that many of these modalities can also
be used in combination with stenting of de novo coronary
lesions and, therefore, can also be viewed as preventing ISR.
For the most part, mechanical and radiation-based therapies
have been used to treat ISR, whereas drug and stent-based
therapies have been used in de novo lesions to try to prevent
ISR. The discussion in the subsequent text follows this
pattern.
Mechanical treatments. PTCA. Percutaneous transluminal
coronary angioplasty—redilating within the segment of
ISR—is the most commonly available treatment. The pro-
cedure is technically straightforward but usually does not
achieve a lumen diameter as large as that achieved at the
time of original stent deployment, even using larger balloons
at high pressures (55). It has been suggested that 56% of the
achieved lumenal enlargement occurs through additional
stent expansion, and 44% is due to a reduction or compres-
sion of NI tissue (55). Intravascular ultrasound studies have
suggested that this NI tissue may undergo reintrusion
through stent struts soon after initial balloon expansion,
leading to an acute loss of benefit (56). In patients with ISR
lesions 10 mm in length (type I or II) treated with PTCA
alone, recurrence of restenosis occurs in 19% to 35%; for
types III or IV, treated with PTCA in combination with
other therapies, recurrence rates are 50% and 83%, respec-
tively (10,55). In view of these generally poor results,
therefore, attention has focused on mechanical techniques
that involve removal of tissue.
DIRECTIONAL CORONARY ATHERECTOMY (DCA). Direc-
tional coronary atherectomy is an attractive option for the
treatment of ISR in that there is some evidence that
pre-existing plaque burden contributes to ISR (57) so that
plaque debulking before stenting using DCA has been
proposed as a technique to lower ISR (58). Directional
coronary atherectomy has been demonstrated to remove NI
tissue within the stent and results in an acute gain in lumen
diameter (57,59). In a small series of 45 patients undergoing
DCA for diffuse ISR, there was a low rate of target lesion
revascularization at 12 months of 28.3% (60). However,
concerns over increased morbidity in general after DCA
(61) and specific concerns over stent strut fracture and
disruption after DCA for ISR (62) have hindered broad
adoption of this technique.
HIGH SPEED ROTATIONAL ATHERECTOMY (HSRA). High
speed rotational atherectomy results in the efficient removal
of NI, and, if followed by PTCA, these acute outcomes can
be improved additionally by further stent expansion and
tissue extrusion. Initial registry data suggest this technique is
feasible and safe, resulting in restenosis rates of 28% at
13-month follow-up (63). However, results of two subse-
quent randomized trials have provided conflicting data. The
first of these, the Randomized Trial of Rotational Atherec-
tomy Versus Balloon Angioplasty for In-Stent Restenosis
(ROSTER), was a single center trial comparing 75 patients
undergoing PTCA with 75 patients undergoing HSRA and
found clinical restenosis rates of 20% versus 43% (p 0.01),
respectively (64). These findings were supported by registry
data suggesting improved one-year outcomes for HSRA
compared with PTCA (65) and satisfactory outcomes in
patients with proximal left anterior descending lesions
treated with HSRA with adjunctive intravascular ultrasound
(66). However, the Angioplasty Versus Rotational Atherec-
tomy for Treatment of In-Stent Restenosis Trial (ARTIST)
demonstrated the opposite effect. For patients with diffuse
ISR (10 mm to 50 mm length), 146 patients undergoing
PTCA had an angiographic restenosis rate of 51.2% com-
pared with 152 patients undergoing HRSA with a resteno-
sis rate of 64.8% (p  0.04) (67).
OTHER DEVICES. Given the lack of a clear benefit for any of
the above techniques, a number of other devices have been
tested in the treatment of ISR. These include laser angio-
plasty, helical atherectomy and the cutting balloon (67–70).
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The cutting balloon used for treatment of ISR has been
associated with improved clinical and angiographic variables
at follow-up in a matched comparison with HSRA, PTCA
and stenting and is currently widely used in a number of
centers (70). Additional stenting within the region of ISR
has also been proposed. This is a straightforward technique
generally giving an improved angiographic result compared
with PTCA alone (71). However, additional stenting may
result in greater procedural creatine kinase-MB release (72),
and the longer-term results are similar to angioplasty alone
(73,74).
Radiation treatment for ISR. Radiation therapy (or
brachytherapy from the Greek “brakhus” meaning short,
referring to the short distance between the intravascular
radiation source and target cells) (75,76) is a recently
proposed therapy for ISR, currently the subject of a number
of clinical trials and debate (77,78). Intravascular radiation is
thought to disrupt cellular deoxyribonucleic acid (DNA)
and actively dividing intimal and medial cells (79). This
mechanism is analogous to radiation therapies used in
conditions of neoplastic and non-neoplastic proliferative
diseases (80). Since a large number of the SMCs contained
in ISR lesions are proliferating, as assessed by immunohis-
tochemistry for proliferating cell nuclear antigen and other
markers of proliferation (16), this approach has been enthu-
siastically explored.
Radiation therapy has been tested from two main sources:
 and  (Table 1) (81). To date, the principal  source
tested has been a locally delivered 132Iridium (Ir) wire
(6,82,83);  sources include a 32Phosphorus (P) wire (84)
and a 32P--emitting stent (85). -radiation derives from
particulate energy in the form of electrons and, therefore,
has limited penetration, with most therapeutic benefit
gained within 2 mm to 3 mm of the source. In contrast,
-radiation is in the form of photons, penetrates well
beyond the vessel wall and is not thought to be completely
shielded by standard lead aprons and shields used in
catheterization laboratories, although the amount of extra
shielding required depends on the total -radiation dose
and is currently the matter of some debate (76,78,86).
Most clinical experience has been with the  source using
a 132Ir wire or ribbon (6,82,83). The GAMMA-I trial and
-Washington Radiation for In-Stent Restenosis (WRIST)
trials randomized 252 and 130 patients with ISR, respec-
tively, to receive percutaneous coronary intervention with
either 132Ir wire or placebo (6,82). The Scripps Coronary
Radiation to Inhibit Proliferation Post Stenting (SCRIPPS)
trial randomized 26 patients to 132Ir wire and 29 patients to
placebo after stenting for restenosis following coronary
intervention, 62% of which was ISR (83). In all three
studies, there were significantly reduced rates of angio-
graphic ISR at six months (21.6% vs. 50.5%; 29.2% vs.
67.7%; 17% vs. 54%, respectively, all p   0.01). Subse-
quent trials in selected subgroups have demonstrated similar
effects (Table 1). The benefit beyond six months, however,
appears less robust. At three-year follow-up of patients in
the SCRIPPS trial, a reduction in ISR for the treatment
group was still evident (33.3% vs. 63.6%, p  0.05), though
the magnitude was less at three years than it was at six
months (48% vs. 69%). There was a continuing loss of
lumenal diameter confined to the treatment group out to
three years, raising the possibility that -radiation may
simply delay ISR rather than reduce it (87).
To date, there is more limited experience using
-radiation, though there are a number of trials ongoing at
the time of writing (81,88).  sources include strontium90
(Sr-90), 90Yttrium (89) and a 32P source wire (84). In the
Stents And Radiation Therapy (START) trial, 485 patients
with ISR 20 mm in length were treated with angioplasty
and irradiation with Sr-90/Y or placebo (81). Angiographic
restenosis at eight months was improved with radiation
(29% vs. 45%, p  0.001), and there was no stent throm-
bosis in the treatment group (81). 90Yttrium has been used
in a dose-finding study in 181 patients after PTCA of de
novo lesions, with stenting performed in 28%. There was a
significant, dose-dependent decrease in restenosis rates up
Table 1. Radiation Treatment for ISR: Clinical Trials
Radiation
Source Trial
Patient
Number
Patient
Group
Lesion Length
(mm)
Restenosis Rates
(Rx vs. Placebo) Ref.
 (Gamma)
132Ir wire Gamma-I 252 ISR  45 33 vs. 55 (6)
 WRIST 130 ISR  47 22 vs. 60 (82)
SCRIPPS 55 62% ISR  30 17 vs. 54 (83)
Long WRIST 120 ISR 36–80 32 vs. 71 (81)
WRIST PLUS* 120 ISR  80 34 (103)
 (Beta)
SR90 START 485 ISR  20 29 vs. 45 (81)
Y90  WRIST* 50 ISR  47 22 (81)
32P wire INHIBIT 332 ISR  22 19 vs. 50 (81)
32P wire PREVENT 105 24% ISR  15 8 vs. 39 (84)
Radioactive Stent
32P stent Milan* 82  10% ISR  28 41% to 52% (85)
*Registry; more detailed trial information is available from reference 81.
INHIBIT  Inhibition of Restenosis Using Beta Irradiation Therapy trial; ISR  in-stent restenosis. Other acronyms as in
Abbreviations and Acronyms box.
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to the maximum used dose of 18 Gy, without an increase in
late complications (89). This source has yet to be used for
the treatment of ISR. In the Proliferation Reduction with
Vascular Energy Trial (PREVENT), a 32P source wire on a
centering catheter was used in three doses of 16 Gy, 20 Gy
and 24 Gy compared with control in a heterogenous group
of 105 patients with ISR (25), post-PTCA restenosis (7) or
de novo lesions (73) treated with either stenting (61%) or
PTCA (39%). In this diverse patient group, restenosis rates
were reduced (8% vs. 39%, p  0.012) with similar effects
across the radiation doses (84). A 32P--emitting stent
implanted for 91% to 93% de novo lesions at a number of
doses reduces intrastent ISR at six months but is associated
with high rates of stent-edge restenosis—the so-called
“candy wrapper” effect (85). Recent data in 22 patients
examining the effects at one year demonstrate ongoing
intrastent luminal loss, suggesting 32P--emitting stents
may also be simply delaying but not preventing ISR (90).
Problems with radiation therapy. Despite recent Food
and Drug Administration approval for two intracoronary
radiation delivery devices, there remain a number of con-
cerns (78,91). The optimal dosage for either - or -based
radiation therapy is not known (92). Doses given in clinical
trials have largely been based on pig studies of stenting or
angioplasty alone, which have suggested that a mean dose of
12 Gy to 18 Gy at a depth of 2 mm is optimal (77). This
issue is important, since these studies in pigs have suggested
that a dose of 10 Gy may even be stimulatory (93), and
prior clinical experience indicates that doses 50 Gy for
Hodgkin’s disease may be associated with late coronary
aneurysm formation or further coronary disease (94). Prac-
tical considerations such as local anatomy and difficulty
centering delivery devices often mean dosing is variable
along the course of a vessel (77,92,95)—concerns recently
born out by clinical trial evidence showing that -radiation
may be less effective in treating long lesions (96). Similar
practical considerations include “geographic miss,” a term
adopted from radio-oncology to describe the development
of a new stenosis at the edge of an irradiated area. This is
reported to be due to the combination of injury and
low-dose radiation and includes the “candy wrapper” effect
observed in relation to 32P--emitting stents (97,98).
Another alternative method of delivery is a liquid 188Re-
filled balloon, which avoids centering difficulties but carries
its own risks (99). Late stent thrombosis has also been
reported in a number of radiation trials, of concern because
of the frequency (6% to 7%) and the timing (3 months)
(77). The Beta-Cath trial documented a stent thrombosis
rate of 6.6% (100); the -WRIST trial reported rates of 7%
(82). Neither trial gave prolonged antiplatelet therapy, and
subsequent approaches of six months and one year anti-
platelet treatment may reduce rates of stent thrombosis
(101,102), although it is notable that in the WRIST PLUS
trial a relatively high rate of 2.5% late stent thrombosis was
still observed with a six month course of clopidogrel and
aspirin (103). There is some evidence that this risk is
reduced if further stenting is not performed after irradiation
(100,104). Other findings within six months of coronary
radiation therapy include coronary aneurysms (105,106) and
acellular, necrotic areas of tissue—so-called “black holes.”
These “black holes” are significant, at least in part, because
they contain proteoglycan and other prothrombotic material
(Serruys PW, unpublished data, 2001) (107). Thus, coro-
nary radiation for ISR appears to show promising early
benefit. The long-term benefits and associated risks, how-
ever, remain unclear (78).
STRATEGIES FOR PREVENTION OF ISR
Stents. There has been great interest in the nature of stents
themselves and the means used to implant them as stimuli
for ISR (108,109). Stent design, composition, length, as
well as stent guidance strategies, such as intravascular
ultrasound and measures of coronary flow have received
considerable attention and are fully discussed elsewhere
(51,110). More recently, there has been great interest in the
possibility that stents may be coated with slowly eluting
antirestenotic agents (111). Polymer-coated stents initially
provoked excessive reactions (112), but subsequent coatings
using phosphorylcholine-based polymers have not had this
effect and may prove a useful drug delivery platform (113).
A number of diverse agents have been shown to elute slowly
from polymer coatings and are associated with reduced NI
formation in animal models (Table 2A). Two agents in
particular have undergone pilot studies in humans
(114,115). The first, sirolimus, is a naturally occurring
compound derived from the streptomyces fungus and stim-
ulates p27kip1 levels causing cyclin-Cdk complex inhibition
and cell cycle arrest (116). In two groups of 15 patients
treated with a sirolimus-coated stent (140 g/cm2), either as
a fast (15 day) or slow (28 day) release formulation,
negligible NI regrowth was observed at four months (114).
The recently reported Rapamycin-Eluting Versus Plain
Polymer Stents (RAVEL) trial randomized 238 patients to
a sirolimus-coated stent or conventional stent for de novo
coronary lesions and found a zero restenosis rate in the
sirolimus group (vs. 26%, p  0.0001), clearly a finding of
huge implications. Similarly, paclitaxel, a naturally occur-
ring compound from the Pacific yew tree with potent
antiproliferative effects, thought to be due to an alteration in
microtubular function, has shown promising early results in
14 patients stented with a paclitaxel derivative impregnated
sleeve incorporated into a stent design (117). Both agents
have now proceeded to clinical trials (Table 2B)
(115,117,118). Clearly there remain questions as to the
most suitable agent, toxicity and how multiple or overlap-
ping drug-eluting stents can be used safely (119). There has
also been the observation that stent-based drug delivery
results in marked spatial variations in delivered drug dose
(120) and reports of late stent thrombosis associated the
paclitaxel stents, although it is unclear whether this is due to
the drug or the polymer sleeve (121).
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Conventional drugs. A large number of conventional, sys-
temically delivered drugs have reduced NI formation in a
variety of animal models, but, with the exceptions of probucol,
these have not translated to reduced restenosis after PTCA in
the human (37,122,123). However, as previously discussed,
ISR is comprised principally of NI formation, whereas reste-
nosis after PTCA is multifactorial (12). Therefore, drugs
inhibiting SMC proliferation and migration might be useful
more specifically in reducing rates of ISR. One such agent is
troglitazone, which appeared to reduce NI formation in a small
series of 52 patients (124). Another agent is tranilast, which
has multiple effects, including inhibition of SMC prolifer-
ation and migration (125), reduces ISR in the porcine
coronary model (126) but appears to show no benefit in
recently completed large Phase III Prevention of Restenosis
with Tranilast and its Outcomes (PRESTO) trial (127).
Nucleic acid-based drugs. Nucleic acid-based drugs pro-
vide novel therapeutic options for the treatment of resteno-
sis as well as other conditions (128). The broad principal
behind nucleic acid-based drugs is to specifically target and
inhibit a regulatory gene that plays an important role in a
pathogenic process, classically by creating a molecule of
ribonucleic acid (RNA) or DNA that undergoes comple-
mentary base pairing with its endogenous target (129).
Nucleic-acid based drugs can broadly be divided into three
main types: antisense (AS), ribozymes (RZs) and
DNAzymes (DZs). Antisense molecules are single-stranded
DNA molecules that form an RNA-DNA duplex with
target messenger RNA (130). Antisense oligodeoxynucle-
otides targeting the proto-oncogenes c-myb and c-myc
inhibit NI formation in rat and pig models of injury
(131–133), including stenting (134). However, to date, the
only reported use of AS to prevent ISR in humans using a
locally delivered AS molecule targeting c-myc showed no
benefit (135). Ribozymes are RNA-based molecules with
the advantage of the ability to cleave their target messenger
RNA in an enzymatic fashion (136,137). An RZ targeting
c-myb inhibits SMC proliferation and NI formation after
balloon injury to the rat carotid artery (138). Similarly, RZs
targeting transforming growth factor-1 also inhibit NI
formation in the rat model (139). A chimeric DNA/RNA
hammerhead RZ targeting proliferating cell nuclear antigen
reduces NI formation by 28% in the pig coronary stent
model (140).
A further refinement to nucleic acid gene targeting
strategies has been the development of DZs. These are
single-stranded DNA molecules with catalytic domains
capable of RNA cleavage at high efficiencies, with added
Table 2. Stent-Based Local Drug Delivery for ISR
A. Animal Studies
Drug Type/Drug Animal Model Polymer Effect
Anti-Inflammatory
Methylpredisone pig PFM 23% AS reduction
Dexamethasone pig PLLA nil
Colchicine pig PLLA nil
Antiproliferative
Sirolimus pig NK 39% to 45% reduction*
Paclitaxel rabbit pLA/pCL 42% NI reduction
pig NA 39.5% NI reduction
Other
Prostacyclin analog pig PLLA 22.9% RA reduction
PTK inhibitor pig PLLA 47% AS reduction
Angiopeptin pig POPZ 29% MLD reduction
B. Human Studies
Drug Mechanism Patient Number Restenosis Rate/Trial
Sirolimus Cdk inhibitor 30 10.4–11.0  3.0 NI%
Sirolimus Cdk inhibitor 238 RAVEL
Paclitaxel/QP2 microtubule stabilizer 14 14  15% CSN%
Paclitaxel/QP2 microtubule stabilizer 32 13% CSA stenosis in 13/13
Paclitaxel/QP2 microtubule stabilizer 400† SCORE†
Batimastat MMP-I inhibitor 350† †
Actinomycin-D multiple 350 ACTION†
M-prednisolone multiple 70† STRIDE†
*Injury scores varied between treatment and control; †ongoing trials.
ACTION Actinomycin Eluting Stent Improves Outcomes by Reducing Neointimal Hyperplasia trial; AS area stenosis;
CSN  cross-sectional narrowing ( neointimal area/stent area); MLD  minimal lumen diameter; MMP  matrix
metalloproteinase inhibitor; M-prednisolone  methylprednisolone; NI  neointima; NK  not known; PC  phosphoryl-
choline; PFM  fluororinated polymethacrylate; PLA/PCL  poly(lactide-10--caprolactone); PLLA  poly-L-lactic acid;
POPZ  polyorganophosphazene; RA  restenosis area; RAVEL  Rapamycin-eluting versus Plain Polymer Stents trial;
SCORE  Study to Compare Restenosis Rates with Paclitaxel following Stenting; STRIDE  Study of Antirestenosis with
the BiodiviYsio Dexamethasone Eluting Stent.
Details of individual studies are available from the authors.
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stability conferred by their DNA structure and base modi-
fications (141,142). Locally delivered DZs targeting the
zinc finger transcription factor Egr-1 inhibit NI formation
in the rat carotid injury model by more than 50%, the first
such demonstration of the use of DZs in vivo (143). More
recently, DZs targeting the human version of Egr-1 have
been shown to inhibit ISR in the porcine coronary stent
model (144).
Recently, the expression profile of a large number of
known genes was identified in human in-stent restenotic
tissue at the time of revascularization (145). One gene
upregulated was FK506 binding protein 12, the receptor for
sirolimus, an intriguing finding given the low rates of ISR
recently reported using sirolimus-coated stents (114,146). A
number of other genes were also identified, raising the
possibility that key mediators of NI formation upregulated
in ISR could systematically be targeted with gene-specific
strategies such as nucleic acid-based methodologies.
Gene transfer. Gene transfer is defined as the direct
introduction of a desirable gene into a local environment,
with the aim of increasing the function of that gene to gain
pathophysiologic benefit (147). As such, gene transfer has
been viewed as having the potential to be more specifically
targeted and more suited to local therapy than conventional
drug treatment. The first description of direct gene transfer
into the vasculature was over a decade ago (148) and has
since been described in a number of cardiovascular contexts
including atherosclerosis, angiogenesis and ischemia (149–
151). Restenosis or ISR, in many ways, has been seen as an
ideal pathogenic process to be treated by gene transfer in
that the onset of the restenotic process is largely known and
the site of restenosis is localized and readily accessible
(152,153).
A large number of gene products have been investigated
as potential targets for gene transfer and tested in both
animals and in preliminary studies in humans (Table 3).
These genes have been selected to attempt modification of
a number of processes focusing on SMC proliferation but
including cell migration, thrombosis and endothelial func-
tion (151,153). Studies have shown a generally consistent
effect in the order of 30% to 70% inhibition of NI formation
and, significantly, a number of these approaches have
entered phase I human trials. Early reports suggest this
approach is well tolerated (154).
Most studies have used adenovirus vectors to achieve gene
transfection, although plasmid DNA, either naked or with
a carrier (usually lipid) molecule, has also been employed
(153). Other alternatives are retroviruses and adeno-
associated viruses (153). Adenoviruses have the advantage as
vectors in that they can produce large amounts of highly
purifed recombinant virus (155). However, there have been
recent concerns that adenoviruses may induce inflammation,
particularly when introduced via the intraluminal route
(156,157) and may promote thrombus formation (158).
These concerns have not yet been reported using naked
plasmid DNA. As to the question of how to achieve local
delivery, catheter-based delivery devices for vascular gene
transfer have been investigated for restenosis, all with
important limitations (159–161). More recently, a high
transfection efficiency has been achieved with a DNA-
Table 3. Gene Transfer Therapies for Restenosis
Animal Studies
Predominant Mechanism Gene Target Animal Model Vector % NI Inhibition
Cell proliferation P53 rat HVJ 80%
fas ligand rat AV 60%
cecropin pig L 90%
PDGF  R rat AV 50%
Cell migration TIMP-1 rat RV 40%
MMP-2 rat AV 53%
Thrombosis hirudin rat AV 35%
plasmin rat AV 53%*
Endothelium eNOS rat HVJ/L 70%
VEGF-C rabbit AV 33%*†
PhVEGF165 rabbit naked 60
PGI2 rat P/L 80%
Human Studies
Gene Target Setting
Patient
Number
Delivery
Method Vector Effect
Lac Z Peripheral artery 18 dispatch catheter AV Uptake in 5% cells
VEGF Coronary stenting 10 dispatch catheter P/L Nil
Peripheral artery PTA 19 hydrogel balloon naked DNA 14/19 minimal
NI hyperplasia
*These studies showed diminished effects at later timepoints; †neointima:media ratio inhibition. Details of individual studies are
available from the authors.
AV  adenovirus; HVJ/L  haemaggluting virus of Japan/liposome; MMP  matrix metalloproteinase; NI  neointima;
PDGF  R  Platelet-derived growth factor  receptor; P/L  plasmid/lipid; PG  prostaglandin; RV  retrovirus; TIMP 
tissue inhibitor of metalloproteinase; VEGF  vascular endothelial growth factor.
189JACC Vol. 39, No. 2, 2002 Lowe et al.
January 16, 2002:183–93 Coronary In-Stent Restenosis
eluting polylactic-polyglycolic acid-coated stent in porcine
arteries (53), suggesting that local gene transfer may be
possible using a coated stent.
While studies of gene transfer for restenosis are still at an
early stage, the results of preliminary human trials are
promising. Moreover, the potential advantages of using
local gene delivery to treat a local iatrogenic process are
significant and likely to see continued research effort (152).
Other treatments. There is the recent suggestion that
novel physical therapies may be useful in the treatment of
ISR: two examples being high-frequency ultrasound and
low-power red laser light (162,163). Ultrasound can inhibit
vascular SMC migration and proliferation, and intravascular
ultrasound at 700 kHz delivered to porcine coronary arteries
for 5 min after stenting reduces cell proliferation at seven
days, and NI thickness at 28 days (162). Low-power red
laser light enhances endothelial cell growth in vitro and in
vivo, and preliminary studies suggest that it is associated
with low rates of ISR (163).
CONCLUSIONS
In-stent restenosis is an emerging pathobiologic process,
histologically comprised largely of NI formation with, until
recently, limited treatment options available for both treat-
ment and prevention. Recent advances in gene modification
and gene transfer therapies and, more particularly, in local
stent-based drug delivery systems make it conceivable that
the incidence of ISR—currently the Achilles’ heel of inter-
ventional cardiology—will now be seriously challenged.
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